Joseph A. Jakubowski

Author

Also Known As

Carsten Henneges, Christopher D. Payne, J A Jakubowski, J JAKUBOWSKI, J. A. JAKUBOWSKI, J. A. Jakubowski, J. Jakubowski, J.A. JAKUBOWSKI, J.A. Jakubowski, JOSEPH A JAKUBOWSKI

188

Publications

11.2K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Daiichi-Sankyo (Japan)Daiichi Sankyo (United States)University of Florida Eli Lilly (United Kingdom)

About

Joseph A. Jakubowski is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	58	4.8K
2	Biochemistry	13	15	1.1K
3	Health Sciences	7	7	765
4	Natural Sciences	6	6	196
5	Public Health	4	4	338

Joseph A. Jakubowski

Publications

10K

Citations

H-Index

Page 1

	Year	Citations
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention Stephen D. Wiviott, Dietmar Trenk, Andrew L. Frelinger, Circulation	2007	874
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes Gilles Montalescot, Leonardo Bolognese, Dariusz Dudek, New England Journal of Medicine	2013	636
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents Dietmar Trenk, Gregg W. Stone, Meinrad Gawaz, Journal of the American College of Cardiology Percutaneous Coronary InterventionThrombosisCardiovascular DiseaseBlood PlateletPharmacology	2012	613
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation John T. Brandt, Christopher D. Payne, Stephen D. Wiviott, American Heart Journal ThrombopoiesisThrombosisClopidogrel Loading DosesCardiovascular DiseaseActive Metabolite Formation	2006	568
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Tomas Jernberg, Christopher D. Payne, Kenneth J. Winters, European Heart Journal	2006	535
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Lars Wallentin, Christoph Varenhorst, Stefan James, European Heart Journal	2007	455
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently Nazar Farid, Christopher D. Payne, D. S. Small, Clinical Pharmacology & Therapeutics	2007	321
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Alan D. Michelson, Andrew L. Frelinger, Eugene Braunwald, European Heart Journal	2009	252
Effect of Ca <sup>2+</sup> on GP IIb-IIIa Interactions With Integrilin David R. Phillips, Ann Arfsten, Lisa Nannizzi‐Alaimo, Circulation	1997	248
Platelet size as a determinant of platelet function. C B Thompson, Joseph A. Jakubowski, P G Quinn, PubMed	1983	238

Page 1